title: [Research of high frequency induced thermotherapy efficiency for treatment of hepatocellular carcinoma].
abstract: OBJECTIVE
  To investigate the effectiveness of high frequency induced thermotherapy in the treatment of hepatocellular carcinoma.
  
  
  METHODS
  We included a 65 proven cases of hepatocellular carcinoma in which the diagnosis was confirmed by pathology, radio-imaging and AFP value. The patients were randomly divided into 2 group by odd or even hospitalization number. A total of 32 patients were enrolled in the TACE + PEI only group and 33 patients were enrolled in the TACE + HITT therapy group.
  
  
  RESULTS
  For the 32 patients in TACE + PEI only therapy group, the 1, 2, and 3 year of survival rates were 73%, 56%, and 23%, respectively, with a median survival of 1.876 years. For patients in the therapy group, the 1, 2, and 3 year survival rates were 87%, 76%, and 51%, respectively, with a median survival of 2.134 years. Survival rate and duration in the therapy group was significantly greater in the combination therapy group compared to the control group (P < 0.05). There was a negative correlation between the effectiveness of combination therapy and the mortality risk (P < 0.05).
  
  
  CONCLUSIONS
  HiTT + TACE can significantly increase survival rate and extend length of survival in patients with hepatocellular carcinoma.
authors.affiliation: Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
authors.forename: Li-Gong
authors.initials: LG
authors.lastname: Lu
authors.forename: Bao-Shan
authors.initials: BS
authors.lastname: Hu
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Luo
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult